Ligne de temps
Marie-Anne Rameix-Welti
Responsable de Structure
01 sept. 2025
publication
Community and Hospital-Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 During the 2023-2024 Season, Lyon, France.
Lire plus01 juil. 2025
publication
Development and evaluation of ELISA serological immunoassays for influenza and respiratory syncytial viruses.
Lire plus01 juil. 2025
11 juin 2025
publication
The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population.
Lire plus04 juin 2025
publication
Improved RSV Neutralization Assay Using Recombinant RSV Expressing Reporter Fluorescent Protein.
Lire plus01 avr. 2025
project
Proposed approach to evaluate the potential of avian influenza viruses of concern to undergo genetic reassortment and acquire an MxA-resistant NP segment
Lire plus01 avr. 2025
publication
Performance of whole genome sequencing for respiratory syncytial virus: insights from the first external quality assessment, France, 2024.
Lire plus01 mars 2025
publication
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
Lire plus20 févr. 2025
01 févr. 2025
publication
Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.
Lire plus01 janv. 2025
01 janv. 2025
publication
Visualization of Respiratory Syncytial Virus RNA Synthesis Sites by Ethynyl Uridine Labeling.
Lire plus01 janv. 2025
publication
Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024.
Lire plus01 janv. 2025
01 nov. 2024
publication
Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein.
Lire plus01 nov. 2024
publication
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Lire plus01 oct. 2024
publication
Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
Lire plus25 juil. 2024
publication
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Lire plus30 juin 2024
08 févr. 2024
publication
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Lire plus01 janv. 2024
publication
Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.
Lire plus01 janv. 2024
publication
Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.
Lire plus01 janv. 2024
publication
Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France.
Lire plus30 sept. 2023
08 sept. 2023
publication
Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein.
Lire plus19 janv. 2023
19 janv. 2023
19 janv. 2023
project
Towards the elucidation of the morphogenesis, organization and functioning of respiratory syncytial virus factories
Lire plus04 janv. 2023
01 janv. 2023
01 janv. 2023
publication
Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies.
Lire plus20 déc. 2022
publication
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.
Lire plus13 déc. 2022
publication
Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection.
Lire plus01 juil. 2022
publication
Respiratory syncytial virus ribonucleoproteins hijack microtubule Rab11 dependent transport for intracellular trafficking.
Lire plus01 avr. 2022
31 mars 2022
01 oct. 2021
publication
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
Lire plus01 oct. 2021
publication
Monocyte distribution width as a biomarker of resistance to corticosteroids in patients with sepsis: the MOCORSEP observational study.
Lire plus01 juil. 2021
publication
Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection.
Lire plus01 juil. 2021
12 févr. 2021
28 janv. 2021
publication
New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution.
Lire plus01 janv. 2021
publication
Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
Lire plus01 nov. 2020
publication
Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study.
Lire plus22 sept. 2020
publication
Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro.
Lire plus01 sept. 2020
29 juil. 2020
publication
Regulatory B Lymphocytes Colonize the Respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-Dependant Manner.
Lire plus15 mai 2020
publication
De novo protein design enables the precise induction of RSV-neutralizing antibodies.
Lire plus01 mai 2020
publication
Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Lire plus01 janv. 2020
publication
A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein.
Lire plus01 janv. 2020
publication
Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection.
Lire plus24 oct. 2019
publication
The Interactome analysis of the Respiratory Syncytial Virus protein M2-1 suggests a new role in viral mRNA metabolism post-transcription.
Lire plus01 sept. 2019
publication
High-throughput screening of active compounds against human respiratory syncytial virus.
Lire plus10 mai 2019
publication
Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.
Lire plus04 avr. 2019
publication
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses.
Lire plus01 févr. 2019
publication
Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.
Lire plus01 janv. 2019
publication
Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections
Lire plus01 mars 2018
publication
RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription.
Lire plus01 févr. 2018
publication
Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.
Lire plus01 févr. 2018
publication
Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.
Lire plus15 sept. 2017
publication
Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus.
Lire plus01 avr. 2017
publication
A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
Lire plus21 févr. 2017
publication
Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.
Lire plus01 févr. 2017
publication
RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.
Lire plus27 juil. 2015
01 avr. 2015
publication
Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.
Lire plus15 janv. 2015
publication
Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis.
Lire plus07 janv. 2015
publication
Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.
Lire plus03 oct. 2014
publication
Visualizing the replication of respiratory syncytial virus in cells and in living mice.
Lire plus21 nov. 2012
publication
Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.
Lire plus01 sept. 2011
publication
Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting.
Lire plus10 août 2011
publication
Influenza virus infection induces the nuclear relocalization of the Hsp90 co-chaperone p23 and inhibits the glucocorticoid receptor response.
Lire plus01 avr. 2011
publication
Monitoring epidemic viral respiratory infections using one-step real-time triplex RT-PCR targeting influenza A and B viruses and respiratory syncytial virus.
Lire plus01 janv. 2011
publication
Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
Lire plus16 nov. 2010
publication
Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.
Lire plus01 févr. 2010
publication
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
Lire plus30 déc. 2009
publication
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).
Lire plus01 sept. 2009
publication
Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.
Lire plus18 févr. 2009
publication
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
Lire plus19 nov. 2008
publication
Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection.
Lire plus25 juil. 2008
publication
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
Lire plus01 janv. 2008
publication
Host restriction of avian influenza viruses at the level of the ribonucleoproteins.
Lire plus01 mai 2007
publication
Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.
Lire plus31 janv. 2007
publication
Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells.
Lire plus01 janv. 2007
publication
Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.
Lire plus28 août 2006
publication
Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
Lire plus26 mars 2005
publication